Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topical Powder Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Glass Ionomer Sealant and Fluoride Varnish Study to Prevent Early Childhood Caries

NCT01129440
View directory record Official record
Conditions
Dental Caries
Interventions
Fluoride Varnish, Glass Ionomer Sealant
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years to 3 Years
Enrollment
597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Ysidro, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 19, 2026, 2:03 PM EDT
Recruiting Phase 2 Interventional

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis

NCT07660835
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
6 Months to 23 Months
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 19, 2026, 2:03 PM EDT
Completed Not applicable Interventional Results available

U.S. Study of Fibrocaps in Surgical Hemostasis

NCT01256164
View directory record Official record
Conditions
Postoperative Hemorrhage
Interventions
Fibrocaps (fibrin sealant), Gelfoam
Device
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 19, 2026, 2:03 PM EDT
Terminated No phase listed Observational

EPR Tumor Oximetry With CE India Ink

NCT03321903
View directory record Official record
Conditions
Neoplasms, Malignant, Breast Neoplasm, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasm, Head and Neck Neoplasms
Interventions
Carlo Erba Ink Injection, EPR Oximetry Measurement
Device · Other
Lead sponsor
Philip Schaner
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Oct 19, 2026, 2:03 PM EDT
Completed Phase 1 Interventional Results available

Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease

NCT01977781
View directory record Official record
Conditions
Ocular GVHD
Interventions
Tacrolimus, Methylprednisolone Sodium Succinate
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 19, 2026, 2:03 PM EDT
Completed Phase 2 Interventional

DMT310-001 Topical in the Treatment of Acne Vulgaris

NCT03536637
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DMT310, Hydrogen Peroxide, Placebo
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
San Diego, California • Saint Joseph, Missouri • Henderson, Nevada + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 19, 2026, 2:03 PM EDT
Suspended Phase 1Phase 2 Interventional

Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.

NCT01122342
View directory record Official record
Conditions
Vaginitis, Dyspareunia, Breast Neoplasms
Interventions
Testosterone propionate
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Pawtucket, Rhode Island • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Oct 19, 2026, 2:03 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Optimizing Pain Control in Transurethral Resection of the Prostate

NCT04102566
View directory record Official record
Conditions
Pain, BPH With Urinary Obstruction, BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms
Interventions
Ibuprofen 600 mg, Education
Drug · Behavioral
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 19, 2026, 2:03 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

NCT05893888
View directory record Official record
Conditions
Oral Squamous Cell Carcinoma
Interventions
PRV211 (Intraoperative Cisplatin System), PRV111 (Cisplatin Transmucosal System), PRV131 (Cisplatin Intratumoral Injectable)
Drug
Lead sponsor
Privo Technologies
Industry
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Duarte, California • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 19, 2026, 2:03 PM EDT
Withdrawn Phase 4 Interventional

Benefit of Topical Hemostatic Powder Containing Hydrophilic Polymer With Potassium Ferrate for Hemostasis Following Nail Surgery

NCT04384679
View directory record Official record
Conditions
Nail Diseases
Interventions
Hydrophilic polymer and potassium ferrate powder
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 19, 2026, 2:03 PM EDT
Completed Phase 3 Interventional Results available

Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical Hemostasis

NCT00491608
View directory record Official record
Conditions
Spinal Surgery, Vascular Surgery
Interventions
rThrombin
Biological
Lead sponsor
ZymoGenetics
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 19, 2026, 2:03 PM EDT
Completed Phase 1 Interventional

A In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract

NCT01630798
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
GI heptapeptide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 19, 2026, 2:03 PM EDT
Completed Phase 3 Interventional

DMT310-009 Topical in the Treatment of Acne Vulgaris

NCT06090721
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DMT310, Placebo
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
9 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Freemont, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 19, 2026, 2:03 PM EDT
Completed Phase 1 Interventional

Study of KCC Peptide Application in the Colon

NCT02156557
View directory record Official record
Conditions
Colon Polyps, Colorectal Cancer, Inflammatory Bowel Disease (IBD)
Interventions
Colon KCC Heptapeptide
Biological
Lead sponsor
Danielle Kim Turgeon
Other
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 19, 2026, 2:03 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effect of 2-DeNT Oral Topical Powder on Minor Recurrent Aphthous Ulcer

NCT02142543
View directory record Official record
Conditions
Minor Recurrent Aphthous Stomatitis Lesions
Interventions
2-DeNT powder, Placebo Comparator
Drug
Lead sponsor
Texas A&M University
Other
Eligibility
12 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 19, 2026, 2:03 PM EDT
Recruiting Phase 2 Interventional

Topical Probiotic Sinus Irrigations for Treating Chronic Sinusitis

NCT05427695
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Lactobacillus sakei proBio65, Isotonic Saline Solution
Drug · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 19, 2026, 2:03 PM EDT
Not yet recruiting Phase 3 Interventional

Implementation of Vancomycin Powder Application in the Emergency Department for Open Fractures

NCT07659886
View directory record Official record
Conditions
Open Fracture
Interventions
Vancomycin (VAN) treatment, Standard Open Fracture Care
Drug · Other
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 19, 2026, 2:03 PM EDT
Completed Phase 3 Interventional Results available

A Study of Fibrocaps™ in Surgical Bleeding

NCT01527357
View directory record Official record
Conditions
Mild or Moderate Surgical Bleeding
Interventions
Fibrocaps, Gelatin sponge
Biological
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 19, 2026, 2:03 PM EDT
Completed Not applicable Interventional

Diabetic Foot Ulcers-Comparing Transforming Powder to Standard of Care

NCT05046158
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Transforming Powder Dressing, Standard of care topical wound agents and dressings
Device · Other
Lead sponsor
ULURU Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Winter Park, Florida • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 19, 2026, 2:03 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU)

NCT06319287
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
PEP (Purified Exosome Product) / TISSEEL
Biological
Lead sponsor
Rion Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Blue Ash, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 19, 2026, 2:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Use of Topical Subgingival Application of Simvastatin Gel in the Treatment of Peri-Implant Mucositis

NCT03400475
View directory record Official record
Conditions
Peri-implant Mucositis
Interventions
Simvastatin, Placebo
Drug · Other
Lead sponsor
Ahmed Mohamed Mahrous
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 19, 2026, 2:03 PM EDT
Completed Early Phase 1 Interventional

Vancomycin and Tobramycin Powder Use in Acute Open Fractures

NCT05849090
View directory record Official record
Conditions
Infections
Interventions
Cephalosporin or clindamycin/vancomycin antibiotics.., Vancomycin and Tobramycin antibiotics.
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 19, 2026, 2:03 PM EDT
Not listed Phase 2 Interventional

DMT310-005 Topical in the Treatment of Acne Rosacea

NCT05108025
View directory record Official record
Conditions
Acne Rosacea
Interventions
Topical Powder, Placebo Topical Powder
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 19, 2026, 2:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety of Synera in Osteoarthritis Pain

NCT01654302
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Synera, Inactive patch
Drug
Lead sponsor
Thomas J. Schnitzer
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 19, 2026, 2:03 PM EDT